Bempedoic Acid

贝派度酸

Report date: 2026/05/02 20:00:18
NMEFirst In Class

Base Information

Drug NameBempedoic Acid
Drug Alias Name贝派度酸acidum bempedoicum本培酸NexletolNEXLETOL +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionATP-citrate synthase inhibitors
TargetsATP-citrate synthase
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaDrug-Related Side Effects and Adverse ReactionsHypercholesterolemia +[12] 
Global Approved IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaDyslipidemias
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/02/21
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesEsperion
China Registration ClassN/A

Develop Information

Active CompaniesBiomedical Research Institute Of New MexicoOMERS Life SciencesHumanis Saglık Anonim Sirketi +[14] 
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaDrug-Related Side Effects and Adverse ReactionsHypercholesterolemia +[10] 
Inactive IndicationsDiabetes Mellitus, Type 2Hypertension

Other Information

ATC CodeC10AX15
Related LinksWikipediaDrugBankKEGG